Participated · Series B · Jul 2026

Claris Biotherapeutics, spun out of the Harvard lab of corneal disease expert Reza Dana, is developing CSB-001 (oremepermin alfa), an eye drop candidate now targeted at limbal stem cell deficiency (LSCD) after an initial neurotrophic keratitis study failed but showed benefit in LSCD patients. The company plans a phase 3 pivotal trial of CSB-001 beginning in the first half of 2027 with a data readout expected within roughly two years. Claris is running a non-interventional natural history study to better understand LSCD and to create a pool of subjects for its phase 3 trial. The biotech has grown from an initial team of five to more than 25 employees and is seeking to establish a physical headquarters. CEO Stephen Brady, who took over June 15, said the company intends to educate providers on diagnosing LSCD and expects to explore additional indications or pipeline expansion if independent and capitalized. Brady also anticipates taking the company public before phase 3 readout, either via IPO or a reverse merger.

Participated · Series A · Sep 2025

Treeline is a clinical-stage biopharma focused on developing medicines for cancer and other serious diseases using internal R&D and leading-edge computational tools. Its pipeline includes small molecules, protein degraders and glues, and targeted therapy ADCs (TT‑ADCs). The company has initiated Phase 1 trials for three programs: TLN-121 (a BCL6 degrader for lymphomas), TLN-372 (a pan‑KRAS inhibitor for KRAS‑altered solid tumors), and TLN-254 (an in-licensed EZH2 inhibitor for T‑cell lymphomas). Treeline’s team and pipeline were built for scaled invention and company longevity and are led by co-founders Josh Bilenker, M.D., and Jeff Engelman. Therapeutic focus spans oncology with efforts also in neurological and autoimmune diseases. Financially, Treeline is privately held and has raised $1.1 billion to date, reflecting substantial capital to advance its clinical programs.

Participated · Equity · May 2024

BridgeBio Oncology Therapeutics (BBOT) is a newly spun-out company from BridgeBio dedicated to creating a pipeline of oral small-molecule drugs for RAS- and PI3K-mutant malignancies. The company’s lead asset, BBO-8520, is a direct KRAS inhibitor that binds both the active and inactive conformations of the protein and is already enrolling mutant non-small cell lung cancer patients in a Phase Ia/Ib study. Its second program, BBO-10203, is a PI3Kα:RAS breaker that disrupts the RAS–PI3Kα interaction; BBOT plans to file an IND in Q2 2024 and begin patient enrollment later this year. A third candidate, BBO-11818, is a pan-KRASG12X inhibitor with an IND submission targeted for early 2025. Beyond these three clinical and near-clinical programs, BBOT is running discovery-stage research to address additional oncogenic drivers within the RAS and PI3K signaling axes. Originally incorporated as TheRas in 2016, the unit operated under a 2017 R&D agreement with Leidos Biomedical Research before its formal spinout. BBOT is led by Eli Wallace (CEO, Oncology R&D) with BridgeBio CEO Neil Kumar serving as a director, and it is currently financed by a recently closed $200 million round that will fund progression of all three pipeline assets into the clinic over the next 12 months.

Participated · Series C · Dec 2023

Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class bifunctional antibodies that combine tumor-targeting with tumor microenvironment modulation. Its lead candidate, BCA101, is a dual-action EGFR/TGF-β inhibitor in an open-label Phase 1/1b dose expansion being evaluated as monotherapy and in combination with pembrolizumab for frontline HPV-negative R/M HNSCC, advanced SqNSCLC, and cutaneous squamous cell carcinoma. Bicara presented positive interim clinical data at ASCO 2023 and ESMO 2023 demonstrating clinically meaningful anti-tumor activity and a tolerable safety profile in frontline HPV-negative R/M HNSCC. Additional data updates from the ongoing Phase 1/1b study, including in advanced SqNSCLC, are anticipated in 2024. Proceeds from the Series C financing will support continued advancement of BCA101. With the completion of the Series C, Bicara has raised $273 million in 2023. Bicara Therapeutics develops first-in-class bifunctional antibodies that combine targeted therapy precision with tumor modulators to deliver immunomodulatory payloads directly to the tumor microenvironment. Its lead asset, BCA101, is an EGFR / TGF-β-trap bifunctional antibody intended to inhibit EGFR and disable TGF-β at the tumor site to improve anti-tumor responses and the therapeutic window. BCA101 is currently enrolling patients in a Phase 1/1b study and the company has reported promising efficacy and safety data, with plans to present additional data at a medical conference in 2023. Bicara is also advancing IND-enabling studies for a second program, BCA356. The company says it intends to execute future clinical studies of BCA101 in the U.S. and Europe. Bicara is based in Cambridge, Mass.

Led · Equity · Aug 2023

COMPASS Pathways develops COMP360, a proprietary synthetic psilocybin formulation delivered with psychological support to treat individuals who do not respond to current therapies. The company has earned FDA Breakthrough Therapy status and the UK ILAP designation for COMP360 in treatment‑resistant depression (TRD). It completed a phase 2b study showing significant symptom improvement with a 25mg dose and has launched the largest‑ever randomized, controlled, double‑blind phase 3 programme for TRD. COMPASS is also running phase 2 trials in PTSD and anorexia nervosa and investing in digital technology to support its therapy. The company announced a large private financing to support its clinical programmes, commercial planning and research through roughly late 2025. Compass Pathways is a London-based mental health care company focused on developing psilocybin therapy for treatment-resistant depression. Its lead program is a large-scale psilocybin therapy clinical trial being conducted at 20 sites across nine countries in Europe and North America. The company received FDA Breakthrough Therapy designation for its psilocybin therapy program in 2018. Compass intends to use the Series B proceeds to expand its lead program, support research into additional indications for psilocybin therapy, advance its preclinical pipeline, develop digital technologies, and establish new academic and clinical research partnerships. Leadership includes CEO and co-founder George Goldsmith and President, Chief Business Officer and co-founder Lars Wilde.